The study evaluated the safety and quality-of-life outcomes for prostate cancer patients treated with stereotactic body radiation therapy (SBRT) that included a focal boost to specific lesions within the prostate.
Approximately 114 patients participated, with results indicating low levels of severe gastrointestinal (GI) or genitourinary (GU) toxicity, even after a median follow-up of 42 months.
Patient-reported outcomes demonstrated no significant long-term negative changes in various quality-of-life domains such as urinary, bowel, hormonal, or sexual health after undergoing the treatment.